U.S. Food and Drug Administration (OPDP / CBER Advertising and Promotional Labeling Branch) · United States
FDA DTC Guidance - Presenting Quantitative Efficacy and Risk Information
FDA recommends that consumer-directed prescription drug promotion stating efficacy or risk numbers give absolute frequencies for the drug and control groups, use consistent formats, and avoid relative-only figures that overstate benefit.
21 U.S.C. 352(n); 21 CFR 202.1(e)(5)-(6); FDA Quantitative Efficacy and Risk DTC Guidance (2023)
What is FDA DTC Guidance - Presenting Quantitative Efficacy and Risk Information?
FDA recommends that consumer-directed prescription drug promotion stating efficacy or risk numbers give absolute frequencies for the drug and control groups, use consistent formats, and avoid relative-only figures that overstate benefit. DTC prescription drug and biologic ads, websites, social posts, videos and patient materials that state numeric efficacy or risk.
general_audience, general_adults_18plus, customers, patients · Prescription Drug · pharma
Where does this rule apply?
United States
Which marketing channels are covered?
all_channels
When does this rule take effect?
2026-10-07
What does this rule require?
FDA recommends that consumer-directed prescription drug promotion stating efficacy or risk numbers give absolute frequencies for the drug and control groups, use consistent formats, and avoid relative-only figures that overstate benefit.
How can marketing teams comply?
DTC prescription drug and biologic ads, websites, social posts, videos and patient materials that state numeric efficacy or risk.
What is FDA DTC Guidance - Presenting Quantitative Efficacy and Risk Information?
FDA recommends that consumer-directed prescription drug promotion stating efficacy or risk numbers give absolute frequencies for the drug and control groups, use consistent formats, and avoid relative-only figures that overstate benefit.
Who does this rule apply to?
general_audience, general_adults_18plus, customers, patients · Prescription Drug · pharma
Data in promotion that are not in the labeling, including real-world evidence, must be consistent with the approved conditions of use and be presented with the study design, limitations and context needed to avoid misleading the reader.
Firm communications to HCPs about unapproved uses must be scientifically sound, kept separate from promotion, free of persuasive elements and accompanied by disclosures: the use is unapproved, the approved uses and labeling, study design and limitations, conflicting data and financial ties.
Unbranded disease-awareness pieces are outside the risk-disclosure rules only while they do not identify or suggest a specific product; brand cues, single-product category claims or a direct bridge to branded content make them promotion.
On character-limited platforms (paid search, short posts, SMS), a prescription drug benefit claim should be accompanied in the same unit by the established name, the most serious risks and a direct link to complete risk information, or the claim should not be made there.
Consumer-directed TV, radio and streaming ads for prescription drugs must include a major statement of the major risks presented in a clear, conspicuous and neutral manner (consumer-friendly language, audio as clear as the rest of the ad, concurrent text on TV, no distractions), plus adequate provision for full labeling.
Claims that a prescription product is safer, more effective, the only or the first compared with other products require substantial evidence, normally head-to-head data, and must be accurately qualified; compounded drugs must not be marketed as FDA-approved or equivalent to a brand.
Request a free compliance scan of your homepage and book a time with Warrant.